Radiofrequency Ablation Outcomes and Safety in Small Kidney Cancer
Follows adults with small kidney cancer treated with radiofrequency ablation, a heat-based treatment.
Plain-language title generated from the registry record
Registry title: Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients
Key facts
- Where
- Brescia, Milan, and Roma, ItalySee the 4 sites
Where in Italy
- Fondazione Poliambulanza Istituto OspedalieroBrescia, ItalyNo longer taking part
- IRCCS Ospedale San RaffaeleMilan, ItalyNo longer taking part
- Istituto Europeo di Onclologia (IEO)Milan, ItalyNo longer taking part
- Policlinico Universitario Campus Bio-MedicoRoma, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Humanitas Hospital, Italy
- Trial code
- NCT07465458
- Record updated
- 16 March 2026
- Original description
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.Read full original descriptionShow less
Radiofrequency Ablation Multicenter Observational Study in Renal Oncology Patients
This observational study is designed to expand the current database available in the literature and the existing knowledge on the outcomes and safety of radiofrequency ablation (RFA) for the treatment of primary renal cell carcinomas in stage T1a. All interventions and subsequent follow-ups are clinical decisions are independent of the study, given its observational nature.
Inclusion: Age ≥18 years; Signed informed consent approved by the Ethics Committee prior to the ablation procedure; RCC in stage T1a (size <4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation; Absence of comorbidities that contraindicate treatment; Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 at baseline screening.
Exclusion: No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.
Patient selection criteria will be those typically established by each participating center t with T1a primary renal tumors for which a Multidisciplinary Tumor Board has indicated as candidates for treatment with radiofrequency ablation.I.